ChrysoeriolCAS# 491-71-4 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 491-71-4 | SDF | Download SDF |
PubChem ID | 5280666 | Appearance | Yellow powder |
Formula | C16H12O6 | M.Wt | 300.3 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Synonyms | Luteolin 3'-methyl ether; 3'-Methoxyapigenin; 3'-O-Methylluteolin; 4',5,7-Trihydroxy 3'-methoxyflavone | ||
Solubility | Soluble in methan | ||
Chemical Name | 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one | ||
SMILES | COC1=C(C=CC(=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O | ||
Standard InChIKey | SCZVLDHREVKTSH-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H12O6/c1-21-14-4-8(2-3-10(14)18)13-7-12(20)16-11(19)5-9(17)6-15(16)22-13/h2-7,17-19H,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Chrysoeriol has antioxidant, antiinflammatory, antitumor, antimicrobial, antiviral, and free radical scavenging activities, it also shows selective bronchodilator effect. 2. Chrysoeriol can potently inhibit the induction of nitric oxide synthase by blocking activator protein 1 (AP-1) activation and its anti-inflammatory effects. 3. Chrysoeriol can potentially serve as a novel cardioprotective agent against doxorubicin (DOX)-induced cardiotoxicity without affecting the antitumor activity of DOX. 4. Chrysoeriol can induce nod genes in rhizobium meliloti. 5. Chrysoeriol can inhibit the downstream signal transduction pathways of platelet-derived growth factor (PDGF)-Rbeta, including ERK1/2, p38, and Akt phosphorylation, suggests that chrysoeriol may be used for the prevention and treatment of vascular diseases and during restenosis after coronary angioplasty. 6. Chrysoeriol can protect MC3T3-E1 cells against hydrogen peroxide-induced inhibition of osteoblastic differentiation. |
Targets | ERK | p38 | Akt | PI3K | mTOR | p21 | AhR | P450 (e.g. CYP17) | NOS | NF-kB | AP-1 | ROS | Potassium Channel |
Chrysoeriol Dilution Calculator
Chrysoeriol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.33 mL | 16.65 mL | 33.3 mL | 66.6001 mL | 83.2501 mL |
5 mM | 0.666 mL | 3.33 mL | 6.66 mL | 13.32 mL | 16.65 mL |
10 mM | 0.333 mL | 1.665 mL | 3.33 mL | 6.66 mL | 8.325 mL |
50 mM | 0.0666 mL | 0.333 mL | 0.666 mL | 1.332 mL | 1.665 mL |
100 mM | 0.0333 mL | 0.1665 mL | 0.333 mL | 0.666 mL | 0.8325 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Luteolin
Catalog No.:BCN5600
CAS No.:491-70-3
- Isosakuranin
Catalog No.:BCN3712
CAS No.:491-69-0
- Baicalein
Catalog No.:BCN5599
CAS No.:491-67-8
- Kaempferide
Catalog No.:BCN5598
CAS No.:491-54-3
- Quercetin-7-O-beta-D-glucopyranoside
Catalog No.:BCN1261
CAS No.:491-50-9
- 4-HQN
Catalog No.:BCC2448
CAS No.:491-36-1
- Valeroidine
Catalog No.:BCN1920
CAS No.:490-96-0
- Gentisic acid
Catalog No.:BCN3408
CAS No.:490-79-9
- 2,5-Dihydroxyacetophenone
Catalog No.:BCN3825
CAS No.:490-78-8
- Homoquinolinic acid
Catalog No.:BCC6570
CAS No.:490-75-5
- Gaultherin
Catalog No.:BCN2482
CAS No.:490-67-5
- Epicatechin
Catalog No.:BCN5597
CAS No.:490-46-0
- Iridin
Catalog No.:BCN6868
CAS No.:491-74-7
- Biochanin A
Catalog No.:BCN1224
CAS No.:491-80-5
- Hemokinin 1 (human)
Catalog No.:BCC5923
CAS No.:491851-53-7
- TCS PIM-1 1
Catalog No.:BCC2447
CAS No.:491871-58-0
- Thermopsidine
Catalog No.:BCN7923
CAS No.:492-02-4
- (+)-Sparteine
Catalog No.:BCC9249
CAS No.:492-08-0
- Plathymenin
Catalog No.:BCN6810
CAS No.:492-12-6
- Butin
Catalog No.:BCN4630
CAS No.:492-14-8
- Kynurenic acid
Catalog No.:BCN2228
CAS No.:492-27-3
- α-D-Glucose
Catalog No.:BCC9197
CAS No.:492-62-6
- Savinin
Catalog No.:BCN5602
CAS No.:493-95-8
- Methyl L-pyroglutamate
Catalog No.:BCN7060
CAS No.:4931-66-2
Chrysoeriol potently inhibits the induction of nitric oxide synthase by blocking AP-1 activation.[Pubmed:16228289]
J Biomed Sci. 2005 Dec;12(6):949-59.
Chrysoeriol is a flavonoid with antioxidant and anti-inflammatory activities. Despite the large number of studies performed on its biological activities, no clear picture of its mode of action has emerged. In the present study, we isolated Chrysoeriol from the leaves of Digitalis purpurea (foxglove), and studied its effect on the induction of the inducible nitric oxide synthase (iNOS) gene, and the mechanism of this induction in Raw264.7 macrophages. Chrysoeriol pretreatment potently inhibited the release of NO in the cells treated with lipopolysaccharide (LPS), and Western blot and RT-PCR analyses revealed that Chrysoeriol inhibited the LPS-induced inductions of iNOS gene. Moreover, it is known that the activations of nuclear factor-kappaB (NF-kappaB) and activator protein 1 (AP-1) are crucial steps in the transcriptional activation of the iNOS gene. Here, we found that Chrysoeriol selectively suppressed AP-1 activation, and that activation of AP-1 is likely to be essential for iNOS induction in LPS-treated macrophages. This presumed inhibitory effect on AP-1 activation by Chrysoeriol may be associated with its potent NO blocking and anti-inflammatory effects.
Inhibitory effects of chrysoeriol on DNA adduct formation with benzo[a]pyrene in MCF-7 breast cancer cells.[Pubmed:20553787]
Toxicology. 2010 Jul-Aug;274(1-3):42-8.
Cytochrome P450 (CYP) 1 families including CYP1A1, 1A2 and 1B1 are well known to be deeply involved in the initiation of several cancers, due to the fact that they activate environmental pro-carcinogens to form ultimate carcinogens. Benzo[a]pyrene (BaP) is one of the major classes of prototypical pro-carcinogen. It is activated by the CYP1 family to its ultimate carcinogenic forms, mainly BaP-7,8-diol-9,10-epoxide (BPDE), and it forms adducts with DNA. This has been recognized to be a major initiation pathway for cancer. Our previous study demonstrated that Chrysoeriol, which is a dietary methoxyflavonoid, selectively inhibited CYP1B1 enzymatic activity and might protect the CYP1B1 related-diseases such as breast cancer. In the present study, we further examined the effects of Chrysoeriol on the other initiation pathway of cancer relating to the CYP1 family with BaP in human breast cancer MCF-7 cells. The effects of Chrysoeriol on the formation of BPDE-DNA adducts were analyzed specifically using the liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. When MCF-7 cells were incubated with 2 microM BaP for 24h, three types of BPDE-dG adducts, especially (+)-trans-BPDE-dG as the dominant adduct, were detected. Co-treatment of MCF-7 cells with 10 microM Chrysoeriol and BaP remarkably reduced (+)-trans-BPDE-dG formation. Chrysoeriol (1-10 microM) dose-dependently inhibited both EROD activity and the gene expressions of CYP1A1, 1B1 and 1A2 stimulated by treatment with BaP. In addition, the same amounts of Chrysoeriol significantly inhibited the binding of BaP to the aryl hydrocarbon receptor (AhR), which is the key factor concerning the induction of the CYP1 families. In conclusion, our results clearly indicate that Chrysoeriol inhibited the formation of BPDE-DNA adducts via regulation of the AhR pathway stimulated by BaP. As a consequence Chrysoeriol may be involved in the chemoprevention of environmental pro-carcinogens such as BaP.
Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro.[Pubmed:21181363]
J Huazhong Univ Sci Technolog Med Sci. 2010 Dec;30(6):734-40.
This study was designed to determine the impact of Chrysoeriol on proliferation and cell cycle progression in the human multiple myeloma cell lines RPMI 8226 and KM3, and its related molecular mechanisms. Chryseoriol was identified by using the phosphorylated AKT-specific cytoblot high throughput assay. CCK-8 assay was employed to examine the growth inhibition rate and IC(50) (48 h) in peripheral blood mononuclear cells (PBMNCs), RPMI 8226 and KM3 cells treated with Chrysoeriol at various concentrations. Cells were labeled with 5-6-carboxyfluorescein diacetate succinimidyl ester (CFSE), and the proliferation dynamics was detected by flow cytometry and analyzed with ModFit software. The cell cycles of RPMI 8226 and KM3 cells were measured by flow cytometry when the IC(50) concentration of Chrysoeriol was adopted. The alterations in cell-cycle related proteins (Cyclin B1, Cyclin D1, p21) and proteins in PI3K-AKT-mTOR pathway were determined by Western blot analysis. The results showed the proliferation of multiple myeloma cells was significantly inhibited by Chrysoeriol, resulting in cell cycle arrest in G(2)/M phase. Chrysoeriol could significantly reduce the expression of p-AKT (s473) and p-4eBP1 (t37/46) protein, meanwhile enhanced Cyclin B1 and p21 protein expression. Similar effects were not observed in PBMNCs from normal donors. It was concluded that Chrysoeriol was a selective PI3K-AKT-mTOR pathway inhibitor. It restrained the proliferation of human multiple myeloma cells, but didn't affect proliferation of PBMNCs from normal donors. It might exhibit the cell cycle regulatory effect via the inhibition of PI3K-AKT-mTOR signal pathway.
Chrysoeriol isolated from Eurya cilliata leaves protects MC3T3-E1 cells against hydrogen peroxide-induced inhibition of osteoblastic differentiation.[Pubmed:20981859]
J Appl Toxicol. 2010 Oct;30(7):666-73.
Chrysoeriol is a flavonoid compound found in several tropical medicinal plants. To elucidate the protective effects of Chrysoeriol isolated from Eurya cilliata on the response of osteoblasts to oxidative stress, osteoblastic MC3T3-E1 cells were incubated with Chrysoeriol and/or H(2)O(2), and markers of osteoblast function and oxidative damage were examined. Chrysoeriol treatment significantly (P < 0.05) reversed the cytotoxic effect of H(2)O(2) and increased collagen content, alkaline phosphatase activity and calcium deposition of osteoblasts in the presence of H(2)O(2). These effects were blocked by ICI182780, suggesting that Chrysoeriol's effect might be partly involved in estrogen action. Moreover, H(2)O(2)-induced reduction of osteocalcin was recovered in the presence of Chrysoeriol. Chrysoeriol significantly (P < 0.05) decreased the production of receptor activator of nuclear factor-kappaB ligand, interleukin-6, protein carbonyl and malondialdehyde of MC3T3-E1 cells in the presence of H(2)O(2). These results demonstrate that Chrysoeriol isolated from E. cilliata can protect osteoblasts from oxidative stress-induced toxicity.
An inhibitory effect of chrysoeriol on platelet-derived growth factor (PDGF)-induced proliferation and PDGF receptor signaling in human aortic smooth muscle cells.[Pubmed:19423953]
J Pharmacol Sci. 2009 May;110(1):105-10. Epub 2009 May 8.
Platelet-derived growth factor (PDGF)-BB is one of the most potent factors in the development and progression of various vascular disorders such as restenosis and atherosclerosis. Chrysoeriol is a flavonoid with antioxidant and anti-inflammatory activities. In this study, we investigated the effect of Chrysoeriol on the proliferation of human aortic smooth muscle cells (HASMC). Chrysoeriol significantly inhibited PDGF (20 ng/mL)-induced migration and [(3)H]-thymidine incorporation into DNA at concentrations of 5 and 10 microM without any cytotoxicity. Chrysoeriol also blocked PDGF-stimulated dissociation of actin filament and inhibited PDGF beta-receptor (Rbeta) phosphorylation in a concentration-dependent manner. As a result, the downstream signal transduction pathways of PDGF-Rbeta, including ERK1/2, p38, and Akt phosphorylation, were also inhibited by Chrysoeriol in the same pattern. These findings suggest that in addition to its antioxidant and anti-inflammatory activities, Chrysoeriol may be used for the prevention and treatment of vascular diseases and during restenosis after coronary angioplasty.
Selective bronchodilatory effect of Rooibos tea (Aspalathus linearis) and its flavonoid, chrysoeriol.[Pubmed:17080260]
Eur J Nutr. 2006 Dec;45(8):463-9.
BACKGROUND: Rooibos tea (Aspalathus linearis) is commonly used for hyperactive gastrointestinal, respiratory and cardiovascular disorders. AIM OF STUDY: The aqueous extract of Rooibos tea (RT) was studied for the possible bronchodilator, antispasmodic and blood pressure lowering activities in an attempt to rationalize some of its medicinal uses. METHODS: Isolated tissue preparations, such as rabbit jejunum, aorta and guinea-pig trachea and atria were set up in appropriate physiological salt solutions and aerated with carbogen. For in vivo studies rats were anesthetized with pentothal sodium and blood pressure was measured through carotid artery cannulation. RESULTS: In jejunum, RT caused a concentration-dependent relaxation of low K(+) (25 mM)-induced contractions, with mild effect on the contractions induced by high K(+) (80 mM). In presence of glibenclamide, the relaxation of low K(+)-induced contractions was prevented. Similarly, cromakalim caused glibenclamide-sensitive inhibition of low K(+), but not of high K(+), while verapamil did not differentiate in its inhibitory effect on contractions produced by the two concentrations of K(+). Like in jejunum, RT caused glibenclamide-sensitive relaxation of low K(+)-induced contractions in trachea and aorta, but with a 20 times higher potency in trachea. In atria, RT was least potent with weak inhibitory effect on atrial force and rate of contractions. RT caused a dose-dependent fall in arterial blood pressure in rats under anesthesia. Among the tested pure compounds of Rooibos, Chrysoeriol showed selective bronchodilator effect. Chrysoeriol (luteolin 3'-methyl ether) is a bioactive flavonoid known for antioxidant, antiinflammatory, antitumor, antimicrobial, antiviral, and free radical scavenging activities. CONCLUSION: These results indicate that the bronchodilator, antispasmodic and blood pressure lowering effects of Rooibos tea are mediated predominantly through K(ATP) channel activation with the selective bronchodilatory effect. This study provides a sound mechanistic basis for the wide medicinal use of Rooibos tea, with the therapeutic potential to be developed for congestive respiratory ailments.